| |
CVD Prevention in clinical practice (European Guidelines on)
ESC Clinical Practice Guidelines
Topics:
Cardiovascular Disease Prevention - Risk Assessment and Management
Current versions available to download
Current translated versions available to download:
Authors
Ian Graham FESC, Chairperson, Dan Atar FESC,Knut Borch-Johnsen, Gudrun Boysen, Gunilla Burell, Renata Cifkova FESC, Jean Dallongeville,Guy De Backer FESC, Shah Ebrahim, Bjørn Gjelsvik, Christoph Herrmann-Lingen, Arno Hoes, Steve Humphries, Mike Knapton, Joep Perk FESC, Silvia G. Priori FESC, Kalevi Pyorala FESC, Zeljko Reiner FESC, Luis M Ruilope FESC, Susana Sans-Menendez, Wilma Scholte Op Reimer, Peter Weissberg FESC, David Aaln Wood FESC, John Yarnell FESC, Jose Luis Zamorano FESC - Other experts who contributed to parts of the guidelines: Edmond Walma,Tony Fitzgerald, Marie Therese Cooney, Alexandra Dudina - Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in ClinicalPractice (Constituted by representatives of nine societies and by invited experts)
Endorsed by:
Table of contents: Full Text (ESC Clinical Practice Guidelines)
|
|
|
The scope of the problem: Past and Future
Scientific background, Practical aspects: coronary artery disease, Heart failure, Aortic aneurysm and dissection, Peripheral arterial disease, Stroke, Practical aspects: prevention and management of stroke |
Prevention strategies and policy issues
Scientific background, Practical aspects: policy issues, Prevention in clinical practice
|
How to evaluate scientific evidence
Scientific background, What is "evidence"?, Grading of evidence, The problems of evidence and guidance, Practical aspects |
Priorities, total risk estimation, and objectives
Introduction, Priorities, Total risk estimation, How do I assess risk ? |
Principles of behaviour change and management of behavioural risk factors
Scientific background, The physicians/caregiver-patient interaction as a means towards behavioural change, Specialized and multimodal interventions, Practical aspects: management of behavioural risk factors
|
Smoking
Scientific background, Practical aspect: prevention and management of smoking
|
Nutrition
Scientific background, Practical aspects: management
|
Overweight and obesity
Scientific background, Body weight and risk, Which index of obesity is the best predictor of cardiovascular risk and cardiovascular risk factors-body mass index (BMI), waist circumference (WC), or waist-hip circumference ratio (WHR)?, Imaging and fat distribution, Practical aspects: managements of obesity and overweight, Physical activity and body weight, Diet and behavioural interventions, Drug treatment of overweight
|
Physical activity
Scientific background, Estimating physical activity, Practical aspects: management
|
Heart rate
Scientific background, Practical aspects: management
|
Blood pressure
Scientific background, Risk stratification and target organ damage, Practical aspects: management of hypertension, Who to treat, How to treat, Antihypertensive drugs, Desirable blood pressure, Duration of treatment
|
Plasma lipids
Scientific background, Practical aspects: management, Should statins be given to all persons with cardiovascular disease?
|
Diabetes
Scientific background, Practical aspects: management
|
The metabolic syndrome
Scientific background, Practical aspects: management |
Psychosocial factors
Scientific background, Practical aspects: management of psychosocial risk factors in clinical practice |
Imflammation markers and haemostatic factors
Scientific background |
Genetic factors
Family history: scientific background, Family history: practical aspects, Phenotypes: scientific background, Genotypes: scientific background, DNA-based tests for risk prediction, Practical aspects, DNA-based tests for risk prediction, Pharmacogenetics, Severe familial dyslipidaemias and coronary heart disease, Familial hypercholesterolaemia (FH), Familial combined hyperlipidaemia (FCH) , Familial high-density lipoprotein deficiency syndromes |
New imaging methods to detect asymptomatic individuals at high risk for cardiovascular events
|
Gender issues: cardiovascular disease prevention in women
Scientific background, Practical aspects |
Renal impairment as a risk factor in cardiovascular disease prevention
Scientific background, Practical aspect: management |
Cardioprotective drug therapy
Scientific background, Antiplatelet therapies, B-Blockers, ACE inibitors, Anticoagulation, Practical aspects: management, Antiplatelet therapy: aspirin, Antiplatelet therapy: clopidogrel, B-Blockers, ACE inhibitors, Calcium channel blockers, Diuretics, Anticoagulation |
Implementation strategies
Scientific background, Barriers to the implementation of guidelines, Doctor-patient relationship, Practical aspects, Important arenas for training, Implementation strategies |
Previous versions
A complete list of ESC Clinical Practice Guidelines (current and previous versions) endorsed by ESC National Society Members is available here
|
|